Vertex presents positive long-term data on casgevy™ (exagamglogene autotemcel) at the american society of hematology (ash) annual meeting and exposition and provides program update

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced longer-term data for casgevy™ (exagamglogene autotemcel) from global clinical trials in people with severe sickle cell disease (scd) or transfusion-dependent beta thalassemia (tdt). casgevy is the first and only approved crispr/cas9 gene-edited therapy. the results, presented at the american society of hematology (ash) annual meeting and exposition, continue to demonstrate the transformative, durable cli.
VRTX Ratings Summary
VRTX Quant Ranking